Mazra Mental Health Center Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2017
NCT03323697
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Mazor MHC | Mazra Mental Health Center

Active Ingredients

Drugs in Phase 2 Trials (3)

escitalopram (lexapro) (1 trial)

pentoxifylline (trental) (1 trial)

sz-05 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 2)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3